Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report

Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report

Abstract Mesenchymal–epithelial transition (MET) exon 14 (METex14) skipping mutation is a rare (3%–4%) driver mutation in non‐small cell lung cancer (NSCLC). Tepotinib, a selective MET inhibitor, has shown promise in treating METex14 skipping‐mutated NSCLC. However, its feasibility for perioperative...

Full description

Bibliographic Details
Main Authors: Rongzhen Li, Xiaoyan Liu, Yan Xu, Jing Zhao, Wei Zhong, Xiaoxing Gao, Minjiang Chen, Mengzhao Wang
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Thoracic Cancer
Subjects:
MET exon 14 skipping mutation
neoadjuvant
non‐small cell lung cancer
tepotinib
Online Access:https://doi.org/10.1111/1759-7714.15459

Internet

https://doi.org/10.1111/1759-7714.15459

Similar Items